Highlights

• Unaudited sales for the 6 months YTD FY21 were up 30% over the previous comparative period (using constant currency and excluding royalties)

• Strong sales performance growth during the quarter with Q2 FY21 up 29% on a constant currency basis

• When including the impact of the strengthening AUD against the USD, sales excluding royalty for H1 were up 24% on last year

• New product launch update

• Regulatory approvals update and schedule - FDA clearance, CE approval in Europe, and NMPA approval in China

• Expansion of senior executive team with two key new hires

• Launch of new “ATCOR Health” division

• Successfully completed Share Purchase Plan raising over $3.2 million closed 31 December 2020

• Group Cash balances of $3.32 million at quarter end which, following the January receipt of the oversubscribed SPP of $3.2m+, provides total adjusted cash reserves of ~$6.55m